¿Cómo Podemos Ayudarle?

Puede haber opciones para ayudarle a cubrir los gastos de RITUXAN HYCELA, independientemente del tipo de seguro médico que posea.

Derivación a Fundaciones Independientes de Asistencia al Copago

Si necesita ayuda con el copago de RITUXAN HYCELA, Genentech BioOncology Access Solutions puede derivarle a una fundación independiente de asistencia al copago.

Una fundación independiente de asistencia al copago es una organización benéfica que proporciona asistencia financiera para medicamentos.

Llame a Genentech BioOncology Access Solutions en el (888) 249-4918 para que le deriven.

Si desea ponerse en contacto directamente con una fundación, puede usar la información que se indica a continuación:

The Leukemia and Lymphoma Society
1311 Mamaroneck Avenue, Suite 310
White Plains, NY 10605
Toll Free: 1-877-557-2672 (877-LLS-COPAY)
www.lls.org/copay

En este momento no hay fondos.

Llame a Genentech Access Solutions en el (866) 4ACCESS /
(866) 422-2377. Quizá le podamos ayudar.

La fundaciones independientes de asistencia al copago tienen sus propias normas para elegibilidad. No podemos garantizarle que una fundación le vaya a ayudar. Solo podemos derivarle para que esta le asista con su estado de salud. Esta información solo se la proporcionamos a modo informativo. No respaldamos ni mostramos preferencia económica por ninguna fundación en particular. Las fundaciones de esta lista no son las únicas que pueden ayudarle.

Derivaciones a la fundación Genentech® Access to Care Foundation

La fundación Genentech® Access to Care Foundation, o GATCF, puede ayudarle a conseguir RITUXAN HYCELA de forma gratuita si cumple los requisitos.

La GATCF ayuda a las personas que:

  • No tienen seguro—personas que no cuentan con un seguro
  • Se consideran sin seguro—personas cuyo seguro médico no cubre los medicamentos
  • Tienen un seguro insuficiente—personas que tienen un seguro médico (incluidos planes de seguro comerciales o públicos), pero pagan más de un importe determinado por RITUXAN HYCELA al año

Se deben cumplir otros criterios de elegibilidad para poder recibir medicamentos gratis a través de la GATCF. Si cumple los requisitos indicados a continuación, puede que sea apto para recibir ayuda.

  • ¿Tiene seguro médico?

  • ¿Los ingresos anuales de su hogar son inferiores a $100,000?

  • ¿Los ingresos anuales de su hogar son inferiores a $150,000?

  • ¿Gasta un 5% o más de los ingresos anuales del hogar en RITUXAN HYCELA y debe abonarlos de su bolsillo?

Podría reunir los requisitos para recibir medicamentos gratis a través de la GATCF

Para solicitar asistencia de la GATCF, debe cumplimentar el formulario PAN y la consulta de su médico debe cumplimentar el formulario SMN. 

Asegúrese de rellenar los apartados 5 y 6 del formulario PAN.

Descargar el SMN y el PAN

Puede Haber Disponibles Otras Opciones

Parece que no reúne los requisitos para recibir medicamentos gratis a través de la GATCF. No obstante, puede que haya otras opciones de asistencia para ayudarle.

Averigüe Qué Opción Puede Ser la Adecuada para Usted

También puede llamar a Genentech BioOncology Access Solutions en el (888) 249-4918 y hablar con uno de nuestros Especialistas.

Tendrá que rellenar los apartados 5 y 6 del formulario PAN para solicitar asistencia a la GATCF.

Si cuenta con un seguro médico, primero debe haber probado otros tipos de asistencia a pacientes para ser apto para recibir medicamentos gratis a través de la GATCF. Esto incluye la Tarjeta de Copago de Genentech BioOncology y la ayuda de fundaciones independientes de asistencia al copago. También debe cumplir otros criterios financieros. Si no tiene seguro, debe cumplir unos criterios financieros diferentes.

Derivaciones a la Tarjeta de Copago de Genentech BioOncology

Genentech BioOncology Access Solutions puede derivarle a la Tarjeta de Copago de Genentech BioOncology. Si usted es elegible, puede ayudarle con los gastos de RITUXAN HYCELA que deba abonar de su bolsillo.

La Tarjeta de Copago de Genentech BioOncology ayuda a los pacientes con un seguro médico comercial. Puede que sea un plan que obtiene a través de su empleador o uno que haya contratado en un Mercado de Seguros Médicos como HealthCare.gov. Para poder calificar, también debe cumplir otros criterios.

Para poder optar a la Tarjeta de Copago de Genentech BioOncology, el paciente debe disponer de un seguro comercial, no debe tener Medicare, Medicaid ni ningún otro seguro público y debe cumplir otros criterios de elegibilidad. También debe aceptar las reglas establecidas en los términos y condiciones del programa. Visite CopayAssistanceNow.com para ver la lista completa de términos y condiciones.

Cómo Trabajar con Genentech BioOncology® Access Solutions

Paso 1

Inscríbase en Genentech BioOncology Access Solutions.

¿Cómo me inscribo?

Paso 2

Trabajamos con usted, con la consulta de su médico, su plan de seguro médico y su farmacia especializada. Podríamos ponernos en contacto con usted para recabar más información.

¿Qué averiguaremos?

Paso 3

Le derivamos a las opciones de asistencia a pacientes.

¿Qué opciones hay?

PAN=siglas en inglés de Autorización del Paciente y Aviso de Solicitud Para Transmitir Información Médica a Genentech Access Solutions y a Genentech® Access to Care Foundation.

SMN=siglas en inglés de Declaración de Necesidad Médica.

Important Safety Information & Indication

What it Treats

RITUXAN HYCELA® (rituximab/hyaluronidase human) is a prescription medicine used to treat adults with:

  • Follicular Lymphoma (FL) as a single-agent therapy in patients whose disease recurred or did not respond to initial treatment
  • Follicular Lymphoma as an initial treatment with chemotherapy and, in patients whose initial treatment was successful, as a single-agent follow-up therapy
  • Follicular Lymphoma as a single agent follow-up therapy for patients who did not progress on initial treatment with CVP chemotherapy
  • Diffuse Large B-Cell Lymphoma (DLBCL) as an initial treatment in combination with CHOP or other anthracycline-based chemotherapy regimens
  • Chronic Lymphocytic Leukemia (CLL) in combination with FC chemotherapy as an initial treatment or as a treatment after disease has recurred

Patients can only receive RITUXAN HYCELA after at least one full dose of intravenous (IV) RITUXAN® (rituximab). Read the IV Rituxan Medication Guide for more information about severe infusion reactions, which usually happen during the first dose with IV Rituxan.

RITUXAN HYCELA is not for use to treat medical conditions other than cancers.

It is not known if RITUXAN HYCELA is safe and effective in children.

Important Safety Information

RITUXAN HYCELA can cause serious side effects that can lead to death, including:

  • Severe skin and mouth reactions: Tell your healthcare provider or get medical help right away if you get any of these symptoms at any time during your treatment with RITUXAN HYCELA: painful sores or ulcers on your skin, lips, or in your mouth; blisters; peeling skin; rash or pustules.
  • Hepatitis B virus (HBV) reactivation: Before you receive RITUXAN HYCELA, your doctor will do blood tests to check for HBV infection. If you have had hepatitis B or are a carrier of hepatitis B virus, receiving RITUXAN HYCELA could cause the virus to become an active infection again. Hepatitis B reactivation may cause serious liver problems including liver failure and death. Your healthcare provider will monitor you for hepatitis B infection during and for several months after you stop receiving RITUXAN HYCELA. Tell your healthcare provider right away if you get worsening tiredness, or yellowing of your skin or white part of your eyes during treatment with RITUXAN HYCELA.
  • Progressive Multifocal Leukoencephalopathy (PML): PML is a rare, serious brain infection caused by a virus that can happen in people who receive RITUXAN HYCELA. People with weakened immune systems can get PML. PML can result in death or severe disability. There is no known treatment, prevention, or cure for PML. Tell your healthcare provider right away if you have any new or worsening symptoms or if anyone close to you notices these symptoms: confusion; dizziness or loss of balance; difficulty walking or talking; decreased strength or weakness on one side of your body; vision problems, such as blurred or loss of vision.
  • Serious allergic reactions and other severe reactions:
    Serious allergic reactions, and reactions due to release of certain substances by the body that can lead to death, can happen with rituximab products, including RITUXAN HYCELA.

Skin reactions at or near the injection site (local), including injection site reactions can happen with RITUXAN HYCELA. Symptoms at or near the injection site may include: pain, swelling, hardness, redness, bleeding, itching, and rash. These reactions sometimes happen more than 24 hours after an injection of RITUXAN HYCELA.

Tell your healthcare provider or get medical help right away if you get any of these symptoms during or after an injection of RITUXAN HYCELA: hives (red itchy welts) or rash; itching; swelling of your lips, tongue, throat, or face; sudden cough; shortness of breath, difficulty breathing, or wheezing; weakness; dizziness or feeling faint; palpitations (feeling like your heart is racing or fluttering); chest pain; fever; chills or shaking chills.

What are possible side effects of RITUXAN HYCELA?

RITUXAN HYCELA can cause serious side effects, including:

  • Tumor Lysis Syndrome (TLS): TLS is caused by the fast breakdown of cancer cells. TLS can cause you to have kidney failure, the need for dialysis treatment, and an abnormal heart TLS can happen within 12 to 24 hours after an injection of RITUXAN HYCELA. Your healthcare provider may do blood tests to check you for TLS. Your healthcare provider may give you medicine to help prevent TLS. Tell your healthcare provider right away if you have any of the following signs or symptoms of TLS: nausea, vomiting, diarrhea, or lack of energy.
  • Serious Infections: Serious infections can happen during and after treatment with RITUXAN HYCELA and can lead to Rituximab products can increase your risk of getting infections and can lower the ability of your immune system to fight infections. Types of serious infections that can happen with RITUXAN HYCELA include bacterial, fungal, and viral infections. After receiving RITUXAN HYCELA, some people have developed low levels of certain antibodies in their blood for a long period of time (longer than 11 months). Some of these people with low antibody levels developed infections. Tell your healthcare provider right away if you have any symptoms of infection: fever; cold symptoms, such as runny nose or sore throat that do not go away; flu symptoms, such as cough, tiredness, and body aches; earache or headache; pain during urination; white patches in the mouth or throat; cuts, scrapes, or incisions that are red, warm, swollen, or painful.
  • Heart Problems: RITUXAN HYCELA may cause chest pain, irregular heartbeats, and heart attack. Your healthcare provider may monitor your heart during and after treatment with RITUXAN HYCELA if you have symptoms of heart problems or have a history of heart problems. Tell your healthcare provider right away if you have chest pain or irregular heartbeats during treatment with RITUXAN HYCELA.
  • Kidney Problems: RITUXAN HYCELA can cause severe kidney problems that can lead to death. Your healthcare provider should do blood tests to check how well your kidneys are working.
  • Stomach and serious bowel problems that can sometimes lead to death: Bowel problems, including blockage or tears in the bowel, can happen if you receive RITUXAN HYCELA with chemotherapy medicines. Tell your healthcare provider right away if you have severe stomach-area (abdomen) pain or repeated vomiting during treatment with RITUXAN HYCELA.

Your healthcare provider will stop treatment with RITUXAN HYCELA if you have severe, serious, or life-threatening side effects.

The most common side effects of RITUXAN HYCELA in people with:

  • FL: infections, low white blood cell count, nausea, constipation, cough, and tiredness.
  • DLBCL: infections, low white blood cell count, loss of hair, nausea, and low red blood cell count.
  • CLL: infections, low white blood cell count, nausea, low platelet count, fever, vomiting, and injection site redness.

Additional Important Safety Information

Before receiving RITUXAN HYCELA, tell your healthcare provider about all of your medical conditions, including if you:

  • Have had a severe reaction to a rituximab product or RITUXAN HYCELA.
  • Have had a recent vaccination or are scheduled to receive vaccinations. Patients should not receive certain vaccines before or during treatment with RITUXAN HYCELA.
  • Are pregnant, plan to become pregnant, are breastfeeding, or plan to breastfeed. Patients should talk to their healthcare provider about the risks to their unborn baby if they receive RITUXAN HYCELA during pregnancy. Females who are able to become pregnant should use effective birth control (contraception) during treatment with RITUXAN HYCELA and for 12 months after the last dose of RITUXAN HYCELA. Patients should talk to their healthcare provider about effective birth control. It is not known if RITUXAN HYCELA passes into the patient’s breast milk. Patients must not breastfeed during treatment and for at least 6 months after receiving their last dose of RITUXAN HYCELA.

These are not all of the possible side effects with RITUXAN HYCELA. Patients should call their doctor for medical advice about side effects.

Please see the full Prescribing Information, including BOXED WARNINGS and Medication Guide, for additional Important Safety Information.

Report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. Report side effects to Genentech at (888) 835- 2555.